GSK vs REX · P/E 13, $103.31B cap vs P/E 15, rev $325.0M
GlaxoSmithKline PLC ADR (GSK) versus REX American Resources Corporation (REX) — a side-by-side from cached financials, not a winner call.
GlaxoSmithKline PLC ADR (GSK) is a drug manufacturers - general company listed on US.
REX American Resources Corporation (REX) is a chemicals company listed on NYSE.
GSK does not have a complete income-statement cache yet.
Latest reported REX revenue for 2026-07-31 was $325.0M. Net income was $62.3M. REX currently screens at market cap $1.43B and trailing P/E 15.5.
GSK currently screens at market cap $103.31B and trailing P/E 13.5. REX currently screens at market cap $1.43B and trailing P/E 15.5.
Not investment advice. Open the GSK and REX stock pages for the full models.
Not investment advice.